Baker BROS. Advisors LP Has $4.80 Million Holdings in Generation Bio Co. (NASDAQ:GBIO)

Baker BROS. Advisors LP raised its stake in shares of Generation Bio Co. (NASDAQ:GBIO) by 61.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 1,944,945 shares of the company’s stock after purchasing an additional 737,988 shares during the period. Baker BROS. Advisors LP’s holdings in Generation Bio were worth $4,804,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of Generation Bio by 0.3% during the third quarter. FMR LLC now owns 5,320,266 shares of the company’s stock valued at $13,141,000 after buying an additional 15,656 shares during the last quarter. Vanguard Group Inc. raised its position in Generation Bio by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,570,456 shares of the company’s stock valued at $10,462,000 after buying an additional 18,205 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Generation Bio by 23.9% during the 2nd quarter. Acadian Asset Management LLC now owns 594,569 shares of the company’s stock valued at $1,675,000 after acquiring an additional 114,734 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Generation Bio by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock worth $1,046,000 after acquiring an additional 8,692 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Generation Bio by 31.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock worth $527,000 after acquiring an additional 44,378 shares in the last quarter. 95.22% of the stock is owned by institutional investors.

Generation Bio Trading Up 6.3 %

GBIO stock opened at $1.52 on Monday. The stock has a market cap of $101.53 million, a P/E ratio of -0.69 and a beta of 2.82. The stock’s fifty day simple moving average is $2.12 and its two-hundred day simple moving average is $2.57. Generation Bio Co. has a 1-year low of $1.13 and a 1-year high of $4.65.

Analyst Ratings Changes

A number of research firms recently weighed in on GBIO. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of Generation Bio in a research report on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Generation Bio in a research note on Wednesday, October 23rd.

Generation Bio Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.